The impact of local treatment of the primary tumor site in node positive and metastatic prostate cancer patients

M Moschini, Francesco Soria, A Briganti, SF Shariat

Research output: Contribution to journalArticlepeer-review


Background:Surgical treatment of the primary tumor in patients with metastatic prostate cancer (mPCa) is gaining traction. We discuss the biological rational and the existing literature on this approach.Methods:We reviewed the literature regarding surgical management of advanced and mPCa disease.Results:Surgical removal of the primary tumor despite metastases is becoming a standard in an increasing number of malignancies. Basic science data support the use of surgical removal of the prostate in metastatic PCa. In addition, durable long-term survival has been reported in patients with node-positive PCa treated with radical prostatectomy (RP) as mono or multimodal approach. Based on these data, several groups have demonstrated the feasibility and safety of RP in the metastatic setting. Retrospective series have also reported an improvement in survival for metastatic patients treated with RP in addition to systemic treatment.Conclusions:Although no level I data exist at this time to support the use of RP in clinically node-positive or mPCa patients, retrospective data together with basic research data and experience from other malignancies suggest that treatment of the primary tumor, in form of a RP, is safe and could improve long-term quality of life and survival. However, prospective evaluations are requested to validate these findings before including in the standard clinical practice.Prostate Cancer and Prostatic Diseases advance online publication, 25 October 2016; doi:10.1038/pcan.2016.52. © 2016 Macmillan Publishers Limited, part of Springer Nature.
Original languageEnglish
Pages (from-to)7-11
Number of pages5
JournalProstate Cancer and Prostatic Diseases
Issue number1
Publication statusPublished - 2017


Dive into the research topics of 'The impact of local treatment of the primary tumor site in node positive and metastatic prostate cancer patients'. Together they form a unique fingerprint.

Cite this